Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Provenge followed by Indoximod in mCRPC
NCT01560923Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Oct 2012
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of indoximod in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Masonic Cancer Center. Started Oct 2012; status: completed.
02
Drugs
indoximod
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01560923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01560923.